119-HR-8000 Journalist Public Summary

Public Summary — H.R. 8000 (END 7‑OH Act)

Headline Summary: Make synthetic 7‑hydroxymitragynine (7‑OH) a Schedule I drug nationwide, while leaving natural kratom leaf itself outside the ban.

What It Does: H.R. 8000 would classify 7‑hydroxymitragynine—and its synthetic equivalents—as a Schedule I controlled substance under the federal Controlled Substances Act. The bill explicitly excludes 7‑OH when it occurs naturally within the kratom plant (Mitragyna speciosa), so it targets lab‑made or isolated 7‑OH products, not kratom leaf. In practical terms, manufacturing or selling stand‑alone synthetic 7‑OH would become illegal at the federal level, while the plant remains unaffected by this bill’s text.

Who’s For It:

• Rep. Gus Bilirakis (R‑FL), the bill’s sponsor.
• Public‑health and law‑enforcement officials who have urged federal control of concentrated 7‑OH, pointing to opioid‑like risks and recent product seizures. (fda.gov)
• State officials who already acted against isolated 7‑OH (for example, Florida’s emergency rule), who argue a federal standard would close gaps across states. (myfloridalegal.com)

Who’s Against It:

• Kratom consumer advocates have warned against any policy that could blur lines between illegal synthetic 7‑OH and lawful kratom, while calling for action against mislabeled or deceptive 7‑OH products. (americankratom.org)
• Some retailers and consumers may worry that enforcement could become confusing if natural kratom products are mistaken for banned 7‑OH concentrates; the bill’s carve‑out aims to prevent that outcome.

What’s Next: As of March 20, 2026, the bill has been introduced in the House and referred to the Energy and Commerce and Judiciary Committees. It now awaits hearings, markups, and potential floor consideration. If it passes the House, it would move to the Senate; identical or similar language would need to pass both chambers and be signed by the President to become law.